Department of Food Science and Biotechnology, Sejong University, 209 Neungdong-ro, Seoul, 05006, South Korea.
J Mol Med (Berl). 2021 Jun;99(6):771-784. doi: 10.1007/s00109-021-02048-4. Epub 2021 Mar 16.
The common phenomenon expected from any anti-cancer drug in use is to kill the cancer cells without any side effects to non-malignant cells. Doxorubicin is an anthracycline derivative anti-cancer drug active over different types of cancers with anti-cancer activity but attributed to unintended cytotoxicity and genotoxicity triggering mitogenic signals inducing apoptosis. Administration of doxorubicin tends to both acute and chronic toxicity resulting in cardiomyopathy (left ventricular dysfunction) and congestive heart failure (CHF). Cardiotoxicity is prevented through administration of different cardioprotectants along with the drug. This review elaborates on mechanism of drug-mediated cardiotoxicity and attenuation principle by different cardioprotectants, with a focus on Hsp27 as cardioprotectant by prevention of drug-induced oxidative stress, cell survival pathways with suppression of intrinsic cell death. In conclusion, Hsp27 may offer an exciting/alternating cardioprotectant, with a wider study being need of the hour, specifically on primary cell line and animal models in conforming its cardioprotectant behaviour.
任何正在使用的抗癌药物都有望产生一种常见的现象，即杀死癌细胞而不对非恶性细胞产生任何副作用。阿霉素是一种蒽环类衍生物抗癌药物，对不同类型的癌症具有抗癌活性，但归因于意外的细胞毒性和遗传毒性，引发有丝分裂信号诱导细胞凋亡。阿霉素的给药会导致急性和慢性毒性，导致心肌病（左心室功能障碍）和充血性心力衰竭（CHF）。通过与药物一起使用不同的心脏保护剂来预防心脏毒性。这篇综述详细阐述了药物介导的心脏毒性的机制和不同心脏保护剂的衰减原理，重点介绍了 Hsp27 作为心脏保护剂，通过预防药物引起的氧化应激、抑制细胞内在死亡的细胞存活途径来发挥作用。总之，Hsp27 可能提供一种令人兴奋的/可替代的心脏保护剂，目前需要更广泛的研究，特别是在原代细胞系和动物模型中，以证实其心脏保护剂的作用。
